Post marketingstudy to evaluate the Safety and Efficacy of Wikoryl Oral Suspension in childre
Phase 4
- Conditions
- Health Condition 1: J00- Acute nasopharyngitis [common cold]
- Registration Number
- CTRI/2021/12/039023
- Lead Sponsor
- Alembic Pharmaceuticals Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age: 2-12 years of age. (6 -40 Kg body weight)
2. Genders Eligible for Study: both Males and Females
3. Patients with confirmed clinical diagnosis of Common cold with fever or allergic rhinitis.
4. Patients whose guardians can adhere to the Protocol
Exclusion Criteria
1. Patients known to be hypersensitive to investigational product
2. Patients with severe hepatic or renal dysfunction
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Wikoryl's efficacy in J00 acute nasopharyngitis in pediatric patients?
How does Wikoryl Oral Suspension compare to standard-of-care treatments for common cold with fever in children?
Are there specific biomarkers that predict response to Wikoryl in allergic rhinitis or common cold with fever?
What are the known or potential adverse events associated with Wikoryl in pediatric populations and how are they managed?
What are the related compounds or competitor drugs to Wikoryl for treating J00 in children and how do they differ in mechanism or efficacy?